Jaguar Health reports Q1 EPS (6c) vs. ($2.39) last year

Reports Q1 revenue $2.4M vs. $1.97M last year. Lisa Conte, Jaguar’s president and CEO, said, “Our paramount near-term clinical activity is our phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel- which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency. Top line results from this pivotal study are expected to be imminent. Gelclair is an FDA-approved prescription product and can be commercialized without any clinical development costs for Jaguar,” added Conte. “We are expanding our footprint beyond HIV-related supportive care to include cancer-related supportive care, and the in-license of Gelclair is a first building block while we await the results from our pivotal Phase 3 OnTarget trial of crofelemer for CTD. We live in the age of targeted therapies, and thanks to these amazing drugs cancer patients are living longer – 5, 10, 20 years. Targeted therapies often lead to more severe side effects, however, and patients want to live, not just survive.”